NEW YORK, March 6, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the start of a multicenter, single arm Phase 2 investigator-sponsored study of palifosfamide (ZIO-201) in patients with recurrent metastatic germ cell (testicular and ovarian) tumors who have relapsed on initial platinum-based therapy and high dose chemotherapy, or patients who are not eligible for high dose chemotherapy. The study is being conducted at the Melvin and Bren Simon Cancer Center at the Indiana University, led by Lawrence Einhorn, M.D., Distinguished Professor of the Department of Medicine, Division of Hematology/Oncology at the School of Medicine. ZIOPHARM is currently conducting Phase 3 trials of palifosfamide in first-line metastatic soft tissue sarcoma (PICASSO 3) and first-line metastatic small cell lung cancer (MATISSE). Dr. Einhorn is the lead principal investigator for the MATISSE trial. The Company expects to announce topline results from PICASSO 3 the last week of this month.
"While treatments for germ cell cancers are often effective, and five-year survival is high, there remains a population for whom relapse or a lack of tolerability lead to poor prognosis," said Dr. Einhorn. "Palifosfamide is in the same molecular class as ifosfamide, an agent that has transformed the treatment of testicular cancer. Our early experience in Phase 1 testing with palifosfamide in patients with resistant testicular and ovarian germ cell tumors is quite encouraging. Data from the Phase 2 study will inform us of how best to advance the use of palifosfamide in these diseases."
The primary endpoint is response rate (CR+PR) of single agent palifosfamide in patients with refractory germ cell tumors. The secondary endpoints include the duration of remission, progression-free survival (PFS), overall survival (OS) and the safety profile of palifosfamide in patients with germ cell tumors. In this trial, twelve patients will be treated with palifosfamide (150 mg/m 2 3 days every 3 weeks for 6 cycles) and, if at least 1 response (RR of ≥ 8.5%) is observed, enrollment will continue to a total of twenty patients to evaluate response rate of single agent palifosfamide. Additionally, the response rate will be assessed every cycle by RECIST v1.1 and by serum AFP and beta-hCG.About ZIOPHARM Oncology, Inc.: ZIOPHARM Oncology is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company's clinical programs include:
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV